EA201170217A1 - Гибридные полипептидные антигены респираторно-синцитиального вируса - Google Patents
Гибридные полипептидные антигены респираторно-синцитиального вирусаInfo
- Publication number
- EA201170217A1 EA201170217A1 EA201170217A EA201170217A EA201170217A1 EA 201170217 A1 EA201170217 A1 EA 201170217A1 EA 201170217 A EA201170217 A EA 201170217A EA 201170217 A EA201170217 A EA 201170217A EA 201170217 A1 EA201170217 A1 EA 201170217A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- respiratory syncytial
- syncytial virus
- hybrid
- antigens
- pcb
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 5
- 241000725643 Respiratory syncytial virus Species 0.000 title abstract 4
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
- C07K14/135—Respiratory syncytial virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8188808P | 2008-07-18 | 2008-07-18 | |
| PCT/CA2009/001021 WO2010006447A1 (en) | 2008-07-18 | 2009-07-17 | Chimeric respiratory syncytial virus polypeptide antigens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201170217A1 true EA201170217A1 (ru) | 2011-08-30 |
Family
ID=41549978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201170217A EA201170217A1 (ru) | 2008-07-18 | 2009-07-17 | Гибридные полипептидные антигены респираторно-синцитиального вируса |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20110177117A1 (https=) |
| EP (1) | EP2324062A4 (https=) |
| JP (1) | JP2011528222A (https=) |
| KR (1) | KR20110045008A (https=) |
| CN (1) | CN102131830A (https=) |
| AU (1) | AU2009270399A1 (https=) |
| BR (1) | BRPI0915960A2 (https=) |
| CA (1) | CA2731194A1 (https=) |
| EA (1) | EA201170217A1 (https=) |
| IL (1) | IL210493A0 (https=) |
| MX (1) | MX2011000668A (https=) |
| WO (1) | WO2010006447A1 (https=) |
| ZA (1) | ZA201100132B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5711972B2 (ja) * | 2007-12-24 | 2015-05-07 | アイディー バイオメディカル コーポレイション オブ ケベック | 組換えｒｓｖ抗原 |
| HUE028085T2 (en) | 2009-06-24 | 2016-11-28 | Glaxosmithkline Biologicals Sa | Recombinant RSV antigens |
| CA2768186A1 (en) | 2009-07-15 | 2011-01-20 | Novartis Ag | Rsv f protein compositions and methods for making same |
| CN106008716B (zh) | 2010-07-07 | 2019-08-13 | 人工细胞科技公司 | 呼吸道合胞病毒抗原组合物和方法 |
| WO2012117377A1 (en) * | 2011-03-02 | 2012-09-07 | Novartis Ag | Combination vaccines with lower doses of antigen and/or adjuvant |
| CA2835644C (en) | 2011-05-13 | 2021-06-15 | Novartis Ag | Pre-fusion rsv f antigens |
| CA2906770A1 (en) * | 2013-03-15 | 2014-09-18 | Vlp Biotech, Inc. | Palivizumab epitope-based virus-like particles |
| US10196438B2 (en) | 2013-04-15 | 2019-02-05 | Janssen Vaccines & Prevention B.V. | Human antibodies binding to RSV G protein |
| EA035846B1 (ru) * | 2013-04-15 | 2020-08-20 | Янссен Вэксинс Энд Превеншн Б.В. | Антитела человека, связывающиеся с g-белком rsv |
| EP2873708B1 (de) | 2013-11-19 | 2019-02-13 | Artimelt AG | Klebstoffzusammensetzung |
| RU2723039C2 (ru) | 2015-12-23 | 2020-06-08 | Пфайзер Инк. | Мутанты белка f rsv |
| US10063211B2 (en) * | 2016-02-03 | 2018-08-28 | Qualcomm Incorporated | Compact bypass and decoupling structure for millimeter-wave circuits |
| CA3012703A1 (en) | 2016-02-03 | 2017-08-10 | Cg Discovery, Inc. | Compositions of influenza hemagglutinin with heterologous epitopes and/or altered maturation cleavage sites |
| CN108265079A (zh) * | 2017-01-02 | 2018-07-10 | 刘昕 | 一种新型呼吸道合胞体病毒pre-F融合蛋白载体的制备方法 |
| EP3932424A4 (en) | 2019-02-28 | 2022-10-12 | KM Biologics Co., Ltd. | Rsv f/g chimeric vaccine |
| CN114685627A (zh) * | 2020-12-28 | 2022-07-01 | 广州更新生物医药科技有限公司 | 一种预防呼吸道合胞病毒的rAAV载体疫苗 |
| WO2025026448A1 (zh) * | 2023-08-03 | 2025-02-06 | 广州穗和生物技术有限公司 | 修饰的呼吸道合胞病毒f蛋白及其用途 |
| WO2025263563A1 (ja) * | 2024-06-20 | 2025-12-26 | Ｋｍバイオロジクス株式会社 | ＲＳＶ ＦＧキメラｍＲＮＡワクチン |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4866034A (en) * | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4436727A (en) * | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US5149650A (en) * | 1986-01-14 | 1992-09-22 | University Of North Carolina At Chapel Hill | Vaccines for human respiratory virus |
| US4877611A (en) * | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| US5057540A (en) * | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| MX9203458A (es) * | 1987-12-23 | 1992-09-01 | Upjohn Co | Segmentos inmunogenicos que contienen glicoproteinas quimericas de las glicoproteinas de virus sincitial respiratorio humano. |
| US4912094B1 (en) * | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| CA2138997C (en) * | 1992-06-25 | 2003-06-03 | Jean-Paul Prieels | Vaccine composition containing adjuvants |
| US5776468A (en) * | 1993-03-23 | 1998-07-07 | Smithkline Beecham Biologicals (S.A.) | Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A |
| FR2718452B1 (fr) * | 1994-04-06 | 1996-06-28 | Pf Medicament | Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation. |
| KR100629028B1 (ko) * | 1998-10-16 | 2006-09-26 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 애쥬번트 시스템 및 백신 |
| WO2002042326A1 (en) * | 2000-11-22 | 2002-05-30 | Biota Scientific Management Pty Ltd | A method of expression and agents identified thereby |
| US7368537B2 (en) * | 2003-07-15 | 2008-05-06 | Id Biomedical Corporation Of Quebec | Subunit vaccine against respiratory syncytial virus infection |
| FR2873378A1 (fr) * | 2004-07-23 | 2006-01-27 | Pierre Fabre Medicament Sa | Complexes immunogenes, leur procede de preparation et leur utilisation dans des compositions pharmaceutiques |
| JP5711972B2 (ja) * | 2007-12-24 | 2015-05-07 | アイディー バイオメディカル コーポレイション オブ ケベック | 組換えｒｓｖ抗原 |
-
2009
- 2009-07-17 US US13/054,651 patent/US20110177117A1/en not_active Abandoned
- 2009-07-17 CA CA2731194A patent/CA2731194A1/en not_active Abandoned
- 2009-07-17 KR KR1020117003662A patent/KR20110045008A/ko not_active Withdrawn
- 2009-07-17 BR BRPI0915960A patent/BRPI0915960A2/pt not_active IP Right Cessation
- 2009-07-17 AU AU2009270399A patent/AU2009270399A1/en not_active Abandoned
- 2009-07-17 JP JP2011517723A patent/JP2011528222A/ja active Pending
- 2009-07-17 CN CN2009801332745A patent/CN102131830A/zh active Pending
- 2009-07-17 MX MX2011000668A patent/MX2011000668A/es active IP Right Grant
- 2009-07-17 WO PCT/CA2009/001021 patent/WO2010006447A1/en not_active Ceased
- 2009-07-17 EP EP09797331A patent/EP2324062A4/en not_active Withdrawn
- 2009-07-17 EA EA201170217A patent/EA201170217A1/ru unknown
-
2011
- 2011-01-05 ZA ZA2011/00132A patent/ZA201100132B/en unknown
- 2011-01-06 IL IL210493A patent/IL210493A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2324062A1 (en) | 2011-05-25 |
| EP2324062A4 (en) | 2012-06-06 |
| CN102131830A (zh) | 2011-07-20 |
| IL210493A0 (en) | 2011-03-31 |
| ZA201100132B (en) | 2011-10-26 |
| WO2010006447A1 (en) | 2010-01-21 |
| US20110177117A1 (en) | 2011-07-21 |
| JP2011528222A (ja) | 2011-11-17 |
| AU2009270399A1 (en) | 2010-01-21 |
| KR20110045008A (ko) | 2011-05-03 |
| MX2011000668A (es) | 2011-07-29 |
| BRPI0915960A2 (pt) | 2019-09-24 |
| CA2731194A1 (en) | 2010-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201170217A1 (ru) | Гибридные полипептидные антигены респираторно-синцитиального вируса | |
| EA201270062A1 (ru) | Вакцина | |
| ES2563646T3 (es) | Composiciones y métodos relacionados con variantes de la proteína A (SpA) | |
| HRP20200871T1 (hr) | Izmjenjeni rsv f proteini i postupci njihove uporabe | |
| RU2013155485A (ru) | Антигены f rsv в конформации "перед слиянием" | |
| WO2018109220A3 (en) | Novel recombinant prefusion rsv f proteins and uses thereof | |
| PE20140986A1 (es) | Proteinas de fusion y vacunas de combinacion que comprenden proteina e y pilina a de haemophilus influenzae | |
| JP2013520172A5 (https=) | ||
| RU2011151877A (ru) | Пептиды, проникающие в клетку | |
| RU2015138530A (ru) | Комбинированная вакцина против респираторно-синцитиального вируса и вируса гриппа | |
| EP3539982A3 (en) | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor | |
| WO2008074867A3 (en) | Anti-fc-receptor single domain antibodies (nanobodies-tm) and therapeutic use | |
| RU2013128896A (ru) | Сконструированные белки повторов, которые связываются с сывороточным альбумином | |
| BRPI0417509A (pt) | molécula de proteìna quimérica de núcleo de vìrus da hepatite b (hbc) recombinante, partìculas, vacina ou inóculo, ácido nucleico, molécula de ácido nucleico recombinante, e, célula hospedeira | |
| HRP20240996T1 (hr) | Prefuzija rsv f proteina i njihova uporaba | |
| WO2012046061A3 (en) | Clostridium difficile antigens | |
| AR077757A1 (es) | Composiciones de proteinas de fusion del virus sincicial respiratorio (rsv) y metodos para su preparacion | |
| DK1373301T3 (da) | Reducering af immunogeniciteten af fusionsproteiner | |
| DK1423419T3 (da) | Hybrid- og tandemekspression af Neisseria-proteiner | |
| ECSP077282A (es) | Proceso para la concentración de anticuerpos y productos terapéuticos de los mismos | |
| JP2014040483A5 (https=) | ||
| AU2016219738A1 (en) | Designer peptide-based PCV2 vaccine | |
| EA200901129A1 (ru) | Нуклеиновые кислоты и полипептиды нового рецептора | |
| EA201190327A1 (ru) | Новые конструкции белка вируса папилломы человека (hpv) и их применение в предупреждении заболевания, вызываемого hpv | |
| PE20120570A1 (es) | Diferenciacion de celulas madre mesenquimales |